Zurcher Kantonalbank Zurich Cantonalbank Buys 5,104 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 28.7% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 22,874 shares of the biopharmaceutical company’s stock after buying an additional 5,104 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Ultragenyx Pharmaceutical were worth $962,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the stock. Smartleaf Asset Management LLC lifted its holdings in Ultragenyx Pharmaceutical by 259.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 493 shares during the last quarter. Human Investing LLC purchased a new stake in Ultragenyx Pharmaceutical during the fourth quarter valued at about $42,000. True Wealth Design LLC purchased a new stake in Ultragenyx Pharmaceutical during the third quarter valued at about $43,000. Van ECK Associates Corp lifted its holdings in Ultragenyx Pharmaceutical by 18.4% during the fourth quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 273 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB purchased a new stake in Ultragenyx Pharmaceutical during the third quarter valued at about $83,000. Institutional investors own 97.67% of the company’s stock.

Wall Street Analyst Weigh In

RARE has been the topic of several recent research reports. Wells Fargo & Company upped their price objective on shares of Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an “overweight” rating in a report on Friday, December 20th. Cantor Fitzgerald reissued an “overweight” rating and issued a $118.00 price target on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 26th. Piper Sandler lowered their price target on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an “overweight” rating on the stock in a report on Monday. JPMorgan Chase & Co. lowered their price target on shares of Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating on the stock in a report on Thursday, November 21st. Finally, Canaccord Genuity Group increased their price target on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a “buy” rating in a report on Tuesday, February 18th. One investment analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $91.71.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other news, CEO Emil D. Kakkis sold 11,727 shares of the firm’s stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $42.23, for a total value of $495,231.21. Following the transaction, the chief executive officer now owns 2,183,985 shares in the company, valued at approximately $92,229,686.55. This trade represents a 0.53 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Karah Herdman Parschauer sold 2,990 shares of the firm’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $42.88, for a total transaction of $128,211.20. Following the completion of the transaction, the executive vice president now owns 54,991 shares in the company, valued at $2,358,014.08. This represents a 5.16 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 136,370 shares of company stock worth $5,751,499 over the last ninety days. Insiders own 5.80% of the company’s stock.

Ultragenyx Pharmaceutical Price Performance

Shares of NASDAQ RARE opened at $38.89 on Friday. Ultragenyx Pharmaceutical Inc. has a one year low of $37.02 and a one year high of $60.37. The firm’s 50 day simple moving average is $41.94 and its two-hundred day simple moving average is $47.62. The stock has a market capitalization of $3.60 billion, a P/E ratio of -6.13 and a beta of 0.67.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The business had revenue of $164.88 million for the quarter, compared to the consensus estimate of $163.23 million. As a group, equities analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.